Compare Nuwellis Inc (NUWE) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Raymond James Financial, Inc. — how do they compare? Nuwellis Inc trades at $0.7 (market cap $2.20M), while Raymond James Financial, Inc. trades at $158.66 (market cap $30.51B). The key difference: Raymond James Financial, Inc. is far larger — about 13868.2× Nuwellis Inc's market cap, and Raymond James Financial, Inc. pays a 1.36% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Raymond James Financial, Inc. for 74 Days on average.
| NUWE | RJF | |
|---|---|---|
Market Cap | $2.20M | $30.51B |
Volume | 121,544 | 1,206,253 |
Sector | Health | Financials |
52-Week High | $146.65 | $181.18 |
52-Week Low | $0.68 | $140.89 |
Typical Hold Time | 26 Days | 74 Days |
Enterprise Value | -$1.52M | $24.37B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Raymond James Financial (RJF) trades at $157.29, down 1.4% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $3.14 surpassing the $2.93 forecast. Revenue growth is steady, reaching $13.84 billion in 2025, while profitability remains strong with a net income margin of 15.37%. Recent corporate news includes executive leadership appointments and a declared quarterly dividend of $0.54 per share.
The outlook is mixed, with a consensus analyst price target of $184.00 suggesting upside potential, but technical indicators signal near-term caution. Key risks include rising expenses and capital market volatility. The absence of sell ratings and solid institutional interest support a fundamentally sound investment case, though investors should weigh the bearish technical momentum against strong fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
